Drug Profile
ASP 1951
Alternative Names: ASP-1951; PTZ-522Latest Information Update: 26 Apr 2022
Price :
$50
*
At a glance
- Originator Potenza Therapeutics
- Developer Astellas Pharma; Potenza Therapeutics
- Class Antibodies; Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action TNFRSF18 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 22 Apr 2022 Discontinued - Phase-I for Solid tumours (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Taiwan, South Korea, Canada, USA (IV)
- 22 Apr 2022 Discontinued - Phase-I for Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in Taiwan, South Korea, Canada, USA (IV)
- 19 Apr 2022 Astellas Pharma completed enrolment in its phase I trial for Solid tumours (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in Canada, South Korea, Taiwan, USA (NCT03799003)